Ultra-high-frequency ECG for Prediction of Left Ventricular Remodeling
1 other identifier
observational
368
1 country
1
Brief Summary
The main goal of the project is to prove that ultra-high-frequency ECG (UHF-ECG) can be used as a diagnostic tool that allows the prediction of patients susceptible to the negative effect of right ventricular myocardial pacing. The prediction will be based on the assessment of electrical dyssynchrony and local depolarization durations of left ventricular depolarization emerging during right ventricular pacing. If proved to be valid in left ventricular negative remodeling prediction, UHF-ECG-derived parameters of ventricular dyssynchrony could be used as markers allowing a lead placement optimization during an implant procedure. This information can help the operator to identify patients with the urgent need for physiological pacing (HB or LBBp) and patients in which a right ventricular myocardial pacing is sufficient and will not lead to the development of the negative left ventricular remodeling.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2021
CompletedFirst Submitted
Initial submission to the registry
May 15, 2021
CompletedFirst Posted
Study publicly available on registry
June 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedMarch 5, 2025
March 1, 2024
4.1 years
May 15, 2021
March 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
negative remodeling prediction
* 5% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG electrical dyssynchrony parameter * 5% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG left ventricular lateral wall delay parameter * 5% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG V6d parameter * 10% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG left ventricular lateral wall delay parameter * 10% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG V6d parameter
1 year from randomization
Secondary Outcomes (2)
RV myocardial to physiological pacing comparison
2 years from randomization
UHF-ECG prediction of clinical outcome
3 years from randomization
Study Arms (2)
myocardial pacing group
patients with the pacing lead placed into the right ventricle to obtain myocardial capture
physiological pacing group
patients with the pacing lead placed into the His bundle or left bundle branch area
Interventions
Eligibility Criteria
360 patients with an indication for permanent pacing due to permanent conduction disease of/below the AV node
You may qualify if:
- expectation of permanent right ventricular pacing with atrio-ventricular delay set to 150/180 ms (130/160 resp.) for sensed/paced atrial events during a follow-up,
- a good quality of images during echocardiography,
- willingness to attend clinical check-ups in the implanting center for at least two years.
- life expectancy of at least 2 years
You may not qualify if:
- planned cardiac surgery or transcatheter aortic valve implantation
- hypertrophic cardiomyopathy
- an indication for implantable cardioverter-defibrillator, biventricular implantable cardioverter-defibrillator, or biventricular pacemaker
- active myocarditis
- cardiac surgery or coronary revascularization in the last ten days
- persistent/permanent atrial fibrillation during randomization
- severe aortic stenosis
- mitral valvular disease with an indication to intervention.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Faculty Hospital Kralovske Vinohradylead
- St. Anne's University Hospital Brno, Czech Republiccollaborator
- Regional Hospital Libereccollaborator
Study Sites (1)
Karol Curila
Prague, 10000, Czechia
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
May 15, 2021
First Posted
June 1, 2021
Study Start
May 1, 2021
Primary Completion
June 1, 2025
Study Completion
December 1, 2025
Last Updated
March 5, 2025
Record last verified: 2024-03